Santaris, Miragen Form miRNA Drug Alliance

Miragen will have the right to use Santaris' locked nucleic acid technology in the development of drugs targeting miRNAs related to cardiovascular disease.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.